(HRTX)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: HRTX
Reported as of: 13 Jan 2023
Net transaction value: -$11,128
SEC form: 4
Accepted by SEC: 17 Jan 2023, 16:36:40 UTC
Prior SEC filing: 01 Dec 2022
Next SEC filing: 20 Jan 2023
Source filing: View source filing
Reporting owner signature: /s/ Lisa Peraza Attorney-in-fact for Barry D. Quart

Key filing fact

Barry D. Quart filed Form 4 for HERON THERAPEUTICS, INC. /DE/ (HRTX) on 17 Jan 2023.

Key facts

This page summarizes Barry D. Quart's Form 4 filing for HERON THERAPEUTICS, INC. /DE/ (HRTX).
6 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 17 Jan 2023, 16:36.

Change

Previous filing in this sequence was filed on 01 Dec 2022.
Current net transaction value: -$11,128.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

HRTX transaction

Common Stock

Other

Transaction value: $5,416
Shares: +1,655
Change %: +1%
Price: $3.27
Shares after: 163,441
Date: 31 Oct 2022
Ownership: Direct
Footnotes: F1

HRTX transaction

Common Stock

Options Exercise

Transaction value
Shares: +3,645
Change %: +2.2%
Price
Shares after: 167,086
Date: 13 Jan 2023
Ownership: Direct
Footnotes: F2

HRTX transaction

Common Stock

Options Exercise

Transaction value
Shares: +16,122
Change %: +9.6%
Price
Shares after: 183,208
Date: 13 Jan 2023
Ownership: Direct
Footnotes: F2

HRTX transaction

Common Stock

Tax liability

Transaction value: $16,544
Shares: -5,219
Change %: -2.8%
Price: $3.17
Shares after: 177,989
Date: 13 Jan 2023
Ownership: Direct
Footnotes: F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

HRTX transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -3,645
Change %: -12%
Price: $0.000000
Shares after: 25,521
Date: 13 Jan 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,645
Exercise price
Footnotes: F2, F4

HRTX transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -16,122
Change %: -12%
Price: $0.000000
Shares after: 114,807
Date: 13 Jan 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 16,122
Exercise price
Footnotes: F2, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Represents shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on October 31, 2022.

Footnote F2

Restricted stock units convert into common stock on a one-for-one basis.

Footnote F3

Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions.

Footnote F4

The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020).

Footnote F5

The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021).